Abstract: |
Imaging plays a fundamental role in the accurate evaluation of tumor response. Response assessment criteria are standardized systems for measuring tumor burden during anticancer treatment. These criteria are used in clinical trials to evaluate the efficacy of new drugs and, in clinical practice, to evaluate the effects of treatment on patients seeking an individualized approach. Several standardized criteria were designed to evaluate response, which always correlates with tumor burden assessment and overall survival. RECIST 1.1 consists of the most widely used therapeutic response method today, dedicated to solid tumors. For lymphomas, other specific criteria are already well established, such as Lugano 2014. The recent advances in oncological treatments, highlighting the advent of targeted therapies and immunotherapy and the improvements in several local therapy techniques, demanded new criteria for assessing therapeutic response, which should be used for some malignant neoplasms addressed with specific treatments. © 2025 Elsevier Inc. All rights reserved. |